Eagle Pharmaceuticals completed the acquisition of Acacia Pharma for $107m.

Eagle Pharmaceuticals, a biopharmaceutical company, completed the acquisition of Acacia Pharma, a specialty pharmaceutical company, for $107m. “We are delighted to announce that we have agreed to terms for the proposed acquisition of Acacia Pharma. This will be a very important acquisition for us, both financially and strategically. In recent years, the pharmaceutical industry has witnessed slower uptake of new products and longer ramp periods. In the face of further challenges brought about by the Covid-19 pandemic, many smaller underfunded companies experienced significant hurdles launching products. We therefore believe that Eagle is well suited to drive uptake of these two new products, building from Acacia Pharma’s established foundation since its launch, through our experienced and specialized hospital-based sales organization with minimal additional infrastructure,” Scott Tarriff, Eagle Pharmaceuticals President and CEO.